Synthesis, binding affinity and structure–activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists
作者:Anna Junker、Artur K. Kokornaczyk、Annelien J. M. Zweemer、Bastian Frehland、Dirk Schepmann、Junichiro Yamaguchi、Kenichiro Itami、Andreas Faust、Sven Hermann、Stefan Wagner、Michael Schäfers、Michael Koch、Christina Weiss、Laura H. Heitman、Klaus Kopka、Bernhard Wünsch
DOI:10.1039/c4ob02397h
日期:——
of such complex, multifactorial disorders. Herein we report on the design, synthesis and biological evaluation of benzo[7]annulene- and [7]annulenothiophene-based selective and dual CCR2 and CCR5 receptor antagonists. Intermediates were designed in such a way that diversification could be introduced at the end of the synthesis. Starting from the lead compound TAK-779 (1), the quaternary ammonium moiety
CCR2和CCR5受体在几种炎性,心血管和自身免疫性疾病的发生和发展中起关键作用。因此,两种受体的双重靶向吸引人作为治疗此类复杂,多因素疾病的有前途的策略。在这里,我们报告基于苯并[7]环戊烯和[7]环噻吩基选择性和双重CCR2和CCR5受体拮抗剂的设计,合成和生物学评估。中间体的设计方式是,可以在合成结束时引入多样化。从铅化合物TAK-779(1),季铵部分被不同的不带电部分交换,4-甲基苯基部分被广泛修饰,苯并[7]环戊烯核心被[7]环戊噻吩系统生物等位取代。萘基衍生物9h代表最有前景的双重拮抗剂(K i(CCR2)= 25 nM,IC 50(CCR5)= 17 nM),而6-异丙氧基-3-吡啶基和4-甲氧羰基苯基衍生物9k和9r显示出更多的抗药性。与CCR5受体相比,CCR2的选择性为20倍(K i = 19 nM)。